Table 4. Association of clinical, biochemical, and therapeutic factors with SVR in patients who completed the scheduled 48-week treatment regimen with pegIFNα and ribavirin.

Variables	Odds ratio	95% CI	p
Male vs. female	2.33	0.91–5.96	0.07
Age ≤40 vs. >40 years	2.17	0.97–4.85	0.06
Weight<75 vs. ≥75 Kg	0.48	0.19–1.18	0.1
CDC stage B vs. A	0.66	0.2–2.17	0.49
CDC stage C vs. A	0.42	0.14–1.26	0.12
HIV viral load<200 vs. ≥200 copies/mL	1.39	0.55–3.5	0.48
HAART (yes vs. no)	0.9	0.33–2.66	0.9
ABC (yes vs. no)	1.46	0.5–4.17	0.48
HCV RNA>800000 vs. ≤800000 IU/mL	0.9	0.4–2.02	0.8
HCV RNA>600000 vs. ≤600000 IU/mL	0.69	0.3–1.56	0.37
HCV RNA>400000 vs. ≤400000 IU/mL	0.54	0.2–1.44	0.22
HCV genotype 2+3 vs. 1+4	4.65	1.85–11.6	0.001
Fibrosis 2–4 vs. 0–1	1.35	0.56–3.3	0.5
Steatosis (yes vs. no)	1.39	0.31–6.14	0.7
CD4≤350 cells/mL	2.96	0.87–10	0.07
EVR (yes vs. no)	>999.999		<0.001
RVR (yes vs. no)	31.2	6.56–148.37	<0.001
pegIFNα 2a vs pegIFNα 2b	1.4	0.65–3.17	0.37

pegIFNα: pegylated interferon alpha. CI: confidence interval. CDC: Centers for Disease Control.

HAART: highly active antiretroviral therapy. ABC: abacavir. EVR: early virological response. RVR: rapid virological response.